Comparing Silo Pharma (NASDAQ:SILO) & Ovid Therapeutics (NASDAQ:OVID)

Silo Pharma (NASDAQ:SILO) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.

Valuation and Earnings

This table compares Silo Pharma and Ovid Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silo Pharma	$70,000.00	52.24	-$4.23 million	($4.36)	-0.53
Ovid Therapeutics	$1.58 million	341.12	-$17.41 million	($0.31)	-8.92

Silo Pharma has higher earnings, but lower revenue than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Silo Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Silo Pharma and Ovid Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Silo Pharma	-6,726.39%	-81.75%	-66.35%
Ovid Therapeutics	-240.11%	-23.64%	-20.52%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Silo Pharma and Ovid Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silo Pharma	1	0	0	0	1.00
Ovid Therapeutics	1	0	7	1	2.89

Ovid Therapeutics has a consensus price target of $5.86, suggesting a potential upside of 111.83%. Given Ovid Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Ovid Therapeutics is more favorable than Silo Pharma.

Institutional & Insider Ownership

5.6% of Silo Pharma shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 3.6% of Silo Pharma shares are held by insiders. Comparatively, 7.0% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Silo Pharma has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500.

Summary

Ovid Therapeutics beats Silo Pharma on 12 of the 15 factors compared between the two stocks.

About Silo Pharma

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

About Ovid Therapeutics

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.